Ipsen Shores Up Cash-Generating Primary Care Business With Sanofi CHC Buy
Executive Summary
Ipsen has picked up five of Sanofi's consumer healthcare products in certain European markets to enable the larger company's deal with Boehringer Ingelheim to proceed. Despite moves by Ipsen to bolster its cash-generating primary care business, some analysts still believe a sale could make good business sense.
You may also be interested in...
Ipsen's New CEO Targets At Least One New Drug Annually 'Forever'
The French pharma under its American CEO plans to transform itself through R&D and M&A, and promises to launch at least one new drug or new valuable indication every year - "forever".
Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.
From Onivyde To OTx: Ipsen Fortifies Oncology with Primary Care Dealmaking
Ipsen's cash-generating primary care business is supporting a flurry of activity in its larger specialty care franchise. The French pharma has just signed a new deal with Italian company Akkadeas Pharma to give it a boost in primary care.